

# Romozosumab added to guideline for management of osteoporosis

11 March 2020



[cardiovascular disease](#) and stroke should not be considered for romozosumab. To maintain bone mineral density gains and reduce fracture risk, treatment with antiresorptive osteoporosis therapy is recommended for postmenopausal women with osteoporosis who have completed a course of romozosumab.

"Romozosumab offers promising results for [postmenopausal women](#) with severe [osteoporosis](#) or who have a history of fractures," a coauthor said in a statement. "It does, however, come with a risk of heart disease, so clinicians need to be careful when selecting patients for this therapy."

**More information:** [Abstract/Full Text](#)

Copyright © 2020 [HealthDay](#). All rights reserved.

(HealthDay)—In an Endocrine Society guideline update, published online in the March issue of the *Journal of Clinical Endocrinology & Metabolism*, recommendations are presented for the use of romozosumab in the pharmacological management of osteoporosis in postmenopausal women.

Dolores Shoback, M.D., from the San Francisco Veterans Affairs Medical Center, and colleagues updated guidelines for the pharmacologic management of osteoporosis in postmenopausal women using romozosumab. Findings were reviewed from a meta-analysis and primary clinical trials assessing the efficacy of romozosumab.

For the reduction of vertebral, hip, and nonvertebral fractures, the authors recommend monthly subcutaneous injections of romozosumab for up to one year for postmenopausal women with osteoporosis at very high risk for fractures. Pending further studies on [cardiovascular risk](#) associated with treatment, women at high risk for

APA citation: Romosozumab added to guideline for management of osteoporosis (2020, March 11) retrieved 2 July 2022 from <https://medicalxpress.com/news/2020-03-romosozumab-added-guideline-osteoporosis.html>

*This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.*